# A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct02851849` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02851849](<https://clinicaltrials.gov/study/NCT02851849>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02851849

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 148 participants.

## Technical summary

Registry record NCT02851849. Randomized; double masking; primary purpose treatment. Start 2016-09 (registry gives no type); primary completion 2017-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 148 participants (enrolled count; ClinicalTrials.gov record NCT02851849, source copy `cardio:ctgov-nct02851849-2018-01-12`, retrieved 2026-10-26)
- Start date: 2016-09 (registry gives no type) (ClinicalTrials.gov record NCT02851849, source copy `cardio:ctgov-nct02851849-2018-01-12`, retrieved 2026-10-26)
- Primary completion: 2017-06 (actual) (ClinicalTrials.gov record NCT02851849, source copy `cardio:ctgov-nct02851849-2018-01-12`, retrieved 2026-10-26)
- Completion: 2017-06 (actual) (ClinicalTrials.gov record NCT02851849, source copy `cardio:ctgov-nct02851849-2018-01-12`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02851849, source copy `cardio:ctgov-nct02851849-2018-01-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02851849-2018-01-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): LGD-6972-5 mg
- Intervention (Drug): LGD-6972-10 mg
- Intervention (Drug): LGD-6972-15 mg
- Intervention (Other): Placebo
- Lead sponsor: Ligand Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study (`cardio:pubmed-31694861`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: ffb30537cca95876b71cd06ce01efe9801ca186e17bcb161de57870241827559
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
